Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch compliance and tolerability in Alzheimer's disease
NCT00731224Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Primary completion
- Oct 2011
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 5
01
Overview
A Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Jul 2008; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00731224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00731224.